ficial multidomain protein, was selected as the model molecule of complex protein with 2 disulfide bonds. A BbFGF-producing plasmid, pJN-BbFGF, and a HBscFv producing-plasmid, pQE-HBscFv, were constructed and transformed into E. coli strains BL21(DE3) and M15[pREP4] respectively. At the same time, both plasmids were transformed into a reductase-deficient host strain, E. coli Origami(DE3). The 4 recombinant E. coli strains were cultured and the target proteins were purified. Solubility and bioactivity of recombinant BbFGF and HBscFv produced in different host strains were analyzed and compared respectively. RESULTS: All recombinant E. coli strains could efficiently produce target proteins. The level of BbFGF in BL21(DE3) was 15-23% of the total protein, and was 5-10% in Origami (DE3). In addition, 65% of the BbFGF produced in BL21(DE3) formed into inclusion body in the cytoplasm, and all the target proteins became soluble in Origami (DE3). The bioactivity of BbFGF purified from Origami(DE3) was higher than its counterpart from BL21(DE3). The ED50 of BbFGF from Origami(DE3) and BL21(DE3) was 1.6μg/L and 2.2μg/L, respectively. Both HBscFv formed into inclusion body in the cytoplasm of M15[pQE-HBscFv] or Origami[pQE-HBscFv]. But the supernatant of Origami [pQE-HBscFv] lysate displayed weak bioactivity and its counterpart from M15[pQE-HBscFv] did not display any bioactivity. The soluble HBscFv in Origami[pQE-HBscFv] was purified to be 1-2 mg/L and its affinity constant was determined to be 2.62×107 mol/L. The yield of native HBscFv refolded from inclusion body in M15[pQE-HBscFv] was 30-35 mg/L and the affinity constant was 1.98×107 mol/L. There was no significant difference between the bioactivity of HBscFvs refolded from the inclusion bodies produced in different host strains. CONCLUSION: Modification of the redox environment of E. coli cytoplasm can significantly improve the folding of recombinant disulfide-bonded proteins produced in it.

目的：研究鲨鱼口服液对15名2型糖尿病病人短期病情控制、症状影响。方法：采用单盲、交叉对照等方法，对鲨鱼口服液受试者的血、尿常规，生化指标、血糖及糖化血清蛋白，以及临床症状等指标进行考察，观察时间为20 d。结果：患者在服用鲨鱼口服液可能改善糖尿病的症状，试验前10.7±6.4分，服用口服液后降为5.8±5.3，与安慰剂对比（P<0.05）。同时该试验品对糖尿病患者的肝、肾、心脏功能及血液学功能等无明显不良影响。结论：鲨鱼口服液在2型糖.尿病患者短期应用安全、可能改善症状、应用简便，但对血糖的影响仍需要长期观察。

为制备纯化的灭活SARS病毒，取广东省CDC提供的灭活SARS-CoV病谳培养液进行超滤，收集相对分子质量介于100000至500000之间的组分。并浓缩。对纯化过程中各组分进行抗原活性签定和蛋白质含量测定。并加佐剂后免疫动物，测定抗体免疫应答。结果表明：超滤后活性抗原蛋白质回收率7.6%，纯化倍数为9，抗原活性达到1∶480 免疫家免获得的血清ELISA效价达到1∶10000以上，中和抗体效价达到1∶2000以上。表明该纯化工艺能获得较高纯度的灭活SARS-CoV病毒颗粒。

目的：研究重组工程菌的遗传稳定性。方法：利用重组表达质粒pBVNM-HI转化宿主菌E.coli DI-LSa，筛选重组工程菌DH5a-pBVNM-HI。将新构建好的重组工程菌在无选择压力的条件下进行连续传代培养，比较菌落在LB（-）和LB（+）培养基上的生长状况，并对传代菌株目标蛋白的表达情况以及质粒数量和目的基因DNA进行电泳鉴定。结果：重组工程菌连续传代5O次中，在LB（-）和LB（+）培养基上的生长状况相同，目标蛋白表达量无显著差异，质粒数量及目的基因DNA结构稳定。结论：重组工程菌DH5a-pBVNM.HI具有良好的遗传稳定性。

目的：探讨灭活SAILS冠状病毒疫苗对小鼠是否有损伤作用。方法：用灭活SARS冠状病毒分别免疫BALB/c和C57BL/6小鼠；ELISA法检测小鼠血清中抗SARS冠状病毒抗体水平；免疫8周后取小鼠各脏器，观察其病理形态学改变。结果：免疫8d后，小鼠血清中就可检测到特异的Ig，M、IgG抗体；组织切片染色观察，可见少数小鼠肺及肝组织出现轻度损伤，其他脏器未见病变。结论：SAILS冠状病毒灭活疫苗可诱导小鼠产生特异性抗体，同时没有造成严重的器官损伤。这将为SARS疫苗进入临床研究打下基础。